| Online-Ressource |
Verfasst von: | Geletneky, Karsten [VerfasserIn]  |
| Hajda, Jacek [VerfasserIn]  |
| Beelte, Birgit [VerfasserIn]  |
| Capper, David [VerfasserIn]  |
| Bartsch, Andreas J. [VerfasserIn]  |
| Neumann, Jan-Oliver [VerfasserIn]  |
| Schöning, Tilman [VerfasserIn]  |
| Hüsing, Johannes [VerfasserIn]  |
| Deimling, Andreas von [VerfasserIn]  |
| Daniel, Volker [VerfasserIn]  |
| Unterberg, Andreas [VerfasserIn]  |
Titel: | Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial |
Verf.angabe: | Karsten Geletneky, Jacek Hajda, Assia L. Angelova, Barbara Leuchs, David Capper, Andreas J. Bartsch, Jan-Oliver Neumann, Tilman Schöning, Johannes Hüsing, Birgit Beelte, Irina Kiprianova, Mandy Roscher, Rauf Bhat, Andreas von Deimling, Wolfgang Brück, Alexandra Just, Veronika Frehtman, Stephanie Löbhard, Elena Terletskaia-Ladwig, Jeremy Fry, Karin Jochims, Volker Daniel, Ottheinz Krebs, Michael Dahm, Bernard Huber, Andreas Unterberg, and Jean Rommelaere |
E-Jahr: | 2017 |
Jahr: | 24 August 2017 |
Umfang: | 15 S. |
Fussnoten: | Gesehen am 02.05.2018 |
Titel Quelle: | Enthalten in: Molecular therapy |
Ort Quelle: | Amsterdam : Elsevier, 2000 |
Jahr Quelle: | 2017 |
Band/Heft Quelle: | 25(2017), 12, Seite 2620-2634 |
ISSN Quelle: | 1525-0024 |
Abstract: | Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was the basis of ParvOryx01, the first phase I/IIa clinical trial of an oncolytic parvovirus in recurrent glioblastoma patients. H-1PV (escalating dose) was administered via intratumoral or intravenous injection. Tumors were resected 9 days after treatment, and virus was re-administered around the resection cavity. Primary endpoints were safety and tolerability, virus distribution, and maximum tolerated dose (MTD). Progression-free and overall survival and levels of viral and immunological markers in the tumor and peripheral blood were also investigated. H-1PV treatment was safe and well tolerated, and no MTD was reached. The virus could cross the blood-brain/tumor barrier and spread widely through the tumor. It showed favorable pharmacokinetics, induced antibody formation in a dose-dependent manner, and triggered specific T cell responses. Markers of virus replication, microglia/macrophage activation, and cytotoxic T cell infiltration were detected in infected tumors, suggesting that H-1PV may trigger an immunogenic stimulus. Median survival was extended in comparison with recent meta-analyses. Altogether, ParvOryx01 results provide an impetus for further H-1PV clinical development. |
DOI: | doi:10.1016/j.ymthe.2017.08.016 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.1016/j.ymthe.2017.08.016 |
| Volltext: http://www.sciencedirect.com/science/article/pii/S1525001617303787 |
| DOI: https://doi.org/10.1016/j.ymthe.2017.08.016 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | clinical trial |
| glioblastoma |
| oncolytic parvovirus |
| tumor microenvironment |
K10plus-PPN: | 1572510722 |
Verknüpfungen: | → Zeitschrift |
Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial / Geletneky, Karsten [VerfasserIn]; 24 August 2017 (Online-Ressource)